文献速递肝胆胰外科围术期管理与 ERAS

非功能性胰腺神经内分泌肿瘤远端胰腺切除术后新发糖尿病的术前预测因素

Preoperative predictors of new-onset diabetes mellitus following distal pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors.
PubMed 文献 · Surgery · 2025-11-07

该研究纳入2015至2022年在San Raffaele医院因局限性非功能性胰腺神经内分泌肿瘤行治愈性远端胰腺切除术的连续患者,排除既往糖尿病和随访不足24个月者。中位随访58个月后,65例中27例(41%)发生术后新发糖尿病。术前体重指数、糖化血红蛋白及肿瘤远端胰腺实质比例较高是术后新发糖尿病的显著危险因素,并据此构建了列线图与在线风险计算器。

要点

  • 远端胰腺切除术后新发糖尿病发生率为41%(27/65)。
  • 术前BMI、糖化血红蛋白及远端胰腺实质比例较高是独立危险因素。
  • 列线图和在线计算器可用于术前个体化风险评估。

核心结论

  • 术后新发糖尿病发生于41%因非功能性胰腺神经内分泌肿瘤行远端胰腺切除术的患者。
  • 术前体重指数升高、糖化血红蛋白升高及肿瘤远端胰腺实质比例较高是术后新发糖尿病的显著危险因素。
  • 所开发的列线图和在线计算器可能支持术前咨询并指导高风险患者的预康复或保留胰腺实质策略。

研究设计与样本

  • 单中心回顾性队列研究,纳入2015至2022年在San Raffaele医院因局限性非功能性胰腺神经内分泌肿瘤行治愈性远端胰腺切除术的连续患者。
  • 排除标准包括既往糖尿病和随访时间小于24个月。
  • 评估临床和影像学数据,中位随访58个月,共65例患者纳入分析。

主要发现

  • 65例患者中27例(41%)在中位随访58个月后发生术后新发糖尿病。
  • 术后新发糖尿病与体重指数升高(P = .016)、胰腺萎缩(P = .044)、总脂肪面积增加(P = .014)和内脏脂肪面积增加(P = .021)以及肿瘤远端胰腺实质比例较高(P = .046)显著相关。
  • Cox回归显示,体重指数较高(风险比:1.187;P = .001)、糖化血红蛋白升高(风险比:1.169;P = .001)和远端胰腺实质比例较高(风险比:1.030;P = .018)是术后新发糖尿病的显著危险因素。
  • 列线图和在线风险计算器预测1年、3年和5年个体风险,区分度良好(曲线下面积:0.766;P < .001)。

关键数值与推荐

  • 术后新发糖尿病定义及诊断标准原文未具体报告。
  • 体重指数每增加1单位,术后新发糖尿病风险比为1.187(P = .001)。
  • 糖化血红蛋白每增加1单位,风险比为1.169(P = .001)。
  • 远端胰腺实质比例每增加1单位,风险比为1.030(P = .018)。
  • 预测模型曲线下面积为0.766(P < .001)。

临床怎么用

  • 对于因非功能性胰腺神经内分泌肿瘤拟行远端胰腺切除术的患者,术前应评估体重指数、糖化血红蛋白及影像学胰腺实质比例。
  • 可使用列线图或在线风险计算器(https://net-distal-pancreatectomy.shinyapps.io/postoperative-diabetes-risk-calculator/)预测1年、3年和5年术后新发糖尿病风险。
  • 对高风险患者,可考虑术前咨询、预康复或保留胰腺实质的手术策略。

局限性

  • 单中心回顾性研究,样本量65例,结论外推需谨慎。
  • 原文未报告术后新发糖尿病的具体定义和诊断标准。
  • 预测模型仅内部验证,缺乏外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonfunctioning pancreatic neuroendocrine tumors are typically indolent neoplasms with a rising incidence. Distal pancreatectomy remains the standard treatment for localized tumors in the pancreatic body/tail. Given the favorable long-term prognosis, accurate assessment of postoperative morbidity, particularly postoperative new-onset diabetes mellitus, is critical. Aims of the study were to identify preoperative predictors of postoperative new-onset diabetes mellitus in patients who underwent distal pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors and to develop a predictive model for individualized risk assessment. METHODS: Consecutive patients who underwent curative distal pancreatectomy for localized nonfunctioning pancreatic neuroendocrine tumors at San Raffaele Hospital between 2015 and 2022 were included. Exclusion criteria included pre-existing diabetes and follow-up <24 months. Clinical and radiological data were evaluated. RESULTS: After a median follow-up of 58 months, 27 of 65 patients (41%) developed postoperative new-onset diabetes mellitus. Postoperative new-onset diabetes mellitus was significantly associated with elevated body mass index (P = .016), pancreatic atrophy (P = .044), increased total (P = .014) and visceral fat area (P = .021), and a higher proportion of pancreatic parenchyma distal to the tumor (P = .046). On Cox regression, higher body mass index (hazard ratio: 1.187; P = .001), elevated hemoglobin A1c (hazard ratio: 1.169; P = .001), and distal higher proportion of pancreatic parenchyma (hazard ratio: 1.030; P = .018) were identified as significant risk factors of postoperative new-onset diabetes mellitus. A nomogram and online risk calculator (https://net-distal-pancreatectomy.shinyapps.io/postoperative-diabetes-risk-calculator/) were developed to predict individual risk at 1, 3, and 5 years, with good discriminatory performance (area under the curve: 0.766; P < .001). CONCLUSION: Postoperative new-onset diabetes mellitus occurred in 41% of patients who underwent distal pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors. Elevated preoperative body mass index, hemoglobin A1c levels, and proportion of distal higher pancreatic parenchyma emerged as significant risk factors of postoperative new-onset diabetes mellitus. The developed nomogram and web-based calculator may support preoperative counseling and guide tailored prehabilitation or parenchyma-sparing strategies in high-risk patients.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Battistella A, Prato F, Andreasi V, et al. Preoperative predictors of new-onset diabetes mellitus following distal pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2025. PMID: 41205334. doi:10.1016/j.surg.2025.109866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。